Revvity (NYSE:RVTY – Get Free Report) issued its quarterly earnings data on Monday. The company reported $1.22 EPS for the quarter, beating analysts’ consensus estimates of $1.12 by $0.10, RTT News reports. Revvity had a return on equity of 7.34% and a net margin of 6.26%. The business had revenue of $691.70 million for the quarter, compared to analyst estimates of $690.33 million. During the same quarter in the prior year, the firm posted $1.21 EPS. The firm’s revenue for the quarter was down 2.5% on a year-over-year basis. Revvity updated its FY 2024 guidance to 4.700-4.800 EPS and its FY24 guidance to $4.70-4.80 EPS.
Revvity Price Performance
Revvity stock traded down $0.78 during trading hours on Thursday, hitting $124.83. 47,601 shares of the stock were exchanged, compared to its average volume of 876,472. Revvity has a 12 month low of $79.50 and a 12 month high of $128.15. The business’s 50-day moving average is $109.63 and its two-hundred day moving average is $106.82. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.92 and a current ratio of 2.27. The stock has a market capitalization of $15.40 billion, a P/E ratio of 103.81, a P/E/G ratio of 3.01 and a beta of 1.05.
Revvity Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, November 8th. Investors of record on Friday, October 18th will be issued a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.22%. The ex-dividend date of this dividend is Friday, October 18th. Revvity’s dividend payout ratio is currently 23.14%.
Wall Street Analysts Forecast Growth
View Our Latest Analysis on RVTY
Insider Buying and Selling at Revvity
In other Revvity news, insider Joel S. Goldberg sold 4,000 shares of the company’s stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $110.46, for a total transaction of $441,840.00. Following the transaction, the insider now directly owns 36,900 shares in the company, valued at approximately $4,075,974. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.60% of the company’s stock.
Revvity Company Profile
Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
See Also
- Five stocks we like better than Revvity
- What Are the FAANG Stocks and Are They Good Investments?
- Mastercard Stock’s Q2 Financial Results Outshine Competitors
- Quiet Period Expirations Explained
- Tobacco Giant’s Shares Fall on EPS Miss, Lackluster Pouch Gains
- Consumer Discretionary Stocks Explained
- Analysts Expect At Least 60% Upside In This Fintech
Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.